Results for Neuroblastoma

1 - 10 of 145

Dr. Maris investigates the molecular and genetic mechanisms contributing to the development and progression of neuroblastoma, a common childhood cancer. He also aims to develop new molecular diagnostic tests and less toxic, targeted therapies to treat relapsed or refractory neuroblastoma, including a major effort in immunotherapy discovery and development.

E-mail:

maris [at] chop.edu

Kristopher R. Bosse, MD

The cure rate for children with neuroblastoma is unacceptable, making it imperative that new therapies are developed. Dr. Bosse's laboratory is focused on discovering and developing new neuroblastoma cell surface immunotherapeutic targets. Along with his colleagues, Dr. Bosse's aim is to capitalize on the robust differential expression of these molecules with immune-based therapies and also define their mechanisms of overexpression and roles in tumorigenesis.

E-mail:

bosse [at] chop.edu

Nicholas F. Evageliou, MD

Dr. Evageliou is an attending physician in the Division of Oncology. His research interest is in renal tumors, neuroblastoma, and solid tumors. He is a member of the Renal Tumors Committee of the Children's Oncology Group, where he helps create clinical trials for Wilms tumors.

E-mail:

evageliou [at] chop.edu

Michael D. Hogarty, MD

Dr. Hogarty is a pediatric oncologist with 20 years' experience as a physician-scientist with a careerlong focus on neuroblastoma translational biology.

E-mail:

hogartym [at] chop.edu

Rochelle Bagatell, MD

Dr. Bagatell’s research focuses on improving therapies for children with neuroblastoma. She leads clinical research studies designed to critically evaluate current therapies for children with high-risk and relapsed disease, and is committed to conducting studies of new therapies for this population. She is currently pursuing research designed to evaluate biomarkers for response to targeted therapy in children with high-risk disease.

E-mail:

bagatellr [at] chop.edu

Kristina A. Cole, MD, PhD

Dr. Cole is a pediatric neuro-oncologist who has dedicated her career to translational and clinical research, combining her expertise in molecular pathology, cancer genomics, and developmental therapeutics to identify novel treatments for children with cancer.

E-mail:

colek [at] chop.edu

Adam J. Wolpaw, MD, PhD

Dr. Wolpaw works on inflammatory signaling in childhood solid tumors, particularly neuroblastoma. The hope is that understanding these pathways and how to modify them will allow us to rationally design approaches to enhance the efficacy of immunotherapies.

E-mail:

wolpawa [at] chop.edu

Garrett M. Brodeur, MD

Dr. Broedur’s research interests focus on nanoparticle drug delivery and cancer predisposition. He is also interested in identifying novel cancer predisposition genes, and developing enhanced surveillance techniques to identify cancer early in predisposed individuals with the hope of improving outcome and reducing side effects.

E-mail:

brodeur [at] chop.edu

Jennifer Pogoriler, MD, PhD

Dr. Pogoriler's research focuses on pediatric lung disease and neoplasia. These interests come together in her work on congenital cystic lung lesions and their potential premalignant diagnosis. She collaborates with both clinicians and basic scientists on pediatric cancer research.

E-mail:

pogorilerj [at] chop.edu

Jessica B. Foster, MD

Dr. Foster’s current research focuses on immunotherapy for pediatric solid and brain tumors. Specifically she is investigating chimeric antigen receptor (CAR) T cell therapy for neuroblastoma, high-grade gliomas, medulloblastomas, diffuse intrinsic pontine gliomas, and other brain tumors. The goals of her research are to develop pre-clinical CAR T cells for translation into clinical trials to help these devastating tumors.

E-mail:

fosterjb [at] chop.edu